SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

PHASE4CompletedINTERVENTIONAL
Enrollment

5,506

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

November 12, 2024

Conditions
Coronary Artery Disease
Interventions
DRUG

Aspirin

"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."

DRUG

Clopidogrel

"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Joo-Yong Hahn

OTHER

NCT04418479 - SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3 | Biotech Hunter | Biotech Hunter